Ansell Limited: Efficiency Gains Offset by Margin Pressures and Unclear Growth Trajectory Support Hold Rating

Ansell (ANSLF) has received a new Hold rating, initiated by Goldman Sachs analyst, Davinthra Thillainathan.

Davinthra Thillainathan has given his Hold rating due to a combination of factors, including Ansell’s successful multi‑year drive to improve manufacturing efficiency contrasted with only modest underlying sales growth over recent years. With a new CEO now tasked with invigorating organic expansion and sharpening the portfolio toward categories with stronger pricing power and brand leverage, the long‑term opportunity is acknowledged but still not clearly defined, so the valuation assumes only limited strategic change.

In the near term, higher oil prices are expected to compress gross margins around FY27 as petrochemical suppliers push through cost increases, with price rises by Ansell likely needed to rebuild margins from FY28, while balance‑sheet strength mitigates some raw‑material and earnings risk. Thillainathan also notes upside optionality from better‑than‑expected pricing and additional cost savings from ERP and SG&A efficiencies, but balances this against downside scenarios of weaker demand or share losses in key product segments, leading to a neutral risk‑reward profile consistent with a Hold view.

Thillainathan covers the Healthcare sector, focusing on stocks such as Ansell, Fisher & Paykel Healthcare Corporation Limited, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. According to TipRanks, Thillainathan has an average return of -1.8% and a 38.10% success rate on recommended stocks.

In another report released on March 26, TipRanks – OpenAI also reiterated a Hold rating on the stock with a A$31.00 price target.